Marker Therapeutics (MRKR) Treasury Shares (2011 - 2018)
Marker Therapeutics (MRKR) reported Treasury Shares of $7561.0 for Q4 2018, down 92.26% year-over-year from $97639.0 in Q4 2017, and down 92.26% quarter-over-quarter from $97639.0 in Q4 2017.
Marker Therapeutics (MRKR) Treasury Shares (2011 - 2018) Analysis & Trends
Marker Therapeutics (MRKR) has 3 years of Treasury Shares data on file, last reported at $7561.0 in Q4 2018.
- Treasury Shares for Q4 2018 came in at $7561.0, down 92.26% year-over-year; the trailing twelve-month figure through Dec 2018 was $7561.0 (down 92.26% YoY), and the FY2018 annual result was $7561.0, down 92.26% from the prior year.
- Treasury Shares slipped to $7561.0 in Q4 2018 per MRKR's latest filing, from $97639.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $97639.0 in Q3 2017 and troughed at $7561.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 7,561.00 |
| Dec 31, 2018 | 7,561.00 |
| Dec 31, 2017 | 97,639.00 |
| Dec 31, 2017 | 97,639.00 |
| Sep 30, 2017 | 97,639.00 |
| Sep 30, 2017 | 97,639.00 |
| Dec 31, 2011 | 1.04 Mn |
| Dec 31, 2011 | 1.04 Mn |
| Jun 30, 2011 | 586,858.00 |
| Jun 30, 2011 | 586,858.00 |